Responses
Poster Presentations
Rheumatoid arthritis - prognosis, predictors and outcome
SAT0070 Baricitinib versus adalimumab in patients with active rheumatoid arthritis: analysis of patients achieving a moderate eular response at week 4
Compose a Response to This Article
Other responses
No responses have been published for this article.